Alto Neuroscience, Inc. (ANRO)

USD 2.44

(-0.41%)

Net Income Summary of Alto Neuroscience, Inc.

  • Alto Neuroscience, Inc.'s latest annual net income in 2023 was -36.3 Million USD , down -31.02% from previous year.
  • Alto Neuroscience, Inc.'s latest quarterly net income in 2024 Q1 was -13.41 Million USD , down -19.61% from previous quarter.
  • Alto Neuroscience, Inc. reported an annual net income of -27.71 Million USD in 2022, down -201.62% from previous year.
  • Alto Neuroscience, Inc. reported an annual net income of -9.18 Million USD in 2021, down 0.0% from previous year.
  • Alto Neuroscience, Inc. reported a quarterly net income of -16.03 Million USD for 2024 Q2, down -19.48% from previous quarter.
  • Alto Neuroscience, Inc. reported a quarterly net income of -8.66 Million USD for 2023 Q2, down -18.93% from previous quarter.

Annual Net Income Chart of Alto Neuroscience, Inc. (2023 - 2021)

Historical Annual Net Income of Alto Neuroscience, Inc. (2023 - 2021)

Year Net Income Net Income Growth
2023 -36.3 Million USD -31.02%
2022 -27.71 Million USD -201.62%
2021 -9.18 Million USD 0.0%

Peer Net Income Comparison of Alto Neuroscience, Inc.

Name Net Income Net Income Difference
ADC Therapeutics SA -240.05 Million USD 84.876%
Annovis Bio, Inc. -56.2 Million USD 35.405%
Biohaven Pharmaceutical Holding Company Ltd. -408.16 Million USD 91.105%
Ginkgo Bioworks Holdings, Inc. -892.86 Million USD 95.934%
Nuvation Bio Inc. -75.8 Million USD 52.105%
Nuvation Bio Inc. -75.8 Million USD 52.105%
Arcus Biosciences, Inc. -307 Million USD 88.174%
Zymeworks Inc. -118.67 Million USD 69.408%